Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results and Host Conference Call on Tuesday, February 4,

Genomic Health to Announce Fourth Quarter and Year-End 2013 Financial Results
            and Host Conference Call on Tuesday, February 4, 2014

PR Newswire

REDWOOD CITY, Calif., Jan. 28, 2014

REDWOOD CITY, Calif., Jan. 28, 2014 /PRNewswire/ -- Genomic Health, Inc.
(Nasdaq: GHDX) today announced that the company will host a conference call
and webcast on Tuesday, February 4 at 4:30 p.m. Eastern Time to discuss its
fourth quarter and year-end 2013 financial results. The call and webcast will
follow the release of the fourth quarter financial results after market close.

(Logo: http://photos.prnewswire.com/prnh/20130425/SF01493LOGO)

Conference Call Details
To access the live conference call on February 4 at 4:30 p.m. Eastern Time via
phone, please dial (877) 303-7208 from the United States and Canada or +1(224)
357-2389 internationally. Please dial in approximately ten minutes prior to
the start of the call.

To access the live and subsequently archived webcast of the conference call,
go to theInvestor Relationssection of the company's website at
http://investor.genomichealth.com. Please connect to the website at least 15
minutes prior to the call to allow for any software download that may be
necessary.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of
genomic-based diagnostic tests that address both the overtreatment and optimal
treatment of early stage cancer, one of the greatest issues in healthcare
today. The company is applying its world-class scientific and commercial
expertise and infrastructure to lead the translation of massive amounts of
genomic datainto clinically-actionable results for treatment planning
throughout the cancer patient's journey, from screening and surveillance,
through diagnosis, treatment selection and monitoring. Genomic Health's lead
product, the Oncotype DX® breast cancer test, has been shown to predict the
likelihood of chemotherapy benefit as well as recurrence in invasive breast
cancer and has been shown to predict the likelihood of recurrence in ductal
carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic
Health provides the Oncotype DX colon cancer test, the first multi-gene
expression test developed for the assessment of risk of recurrence in patients
with stage II and stage III disease, and the Oncotype DX prostate cancer test,
which predicts disease aggressiveness in men with low risk disease. As of
September 30, 2013, more than 19,000 physicians in over 70 countries had
ordered nearly 400,000 Oncotype DX tests. The company is based in Redwood
City, California with European headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and follow the company on
Twitter: @GenomicHealth. To learn more about OncotypeDX tests, visit:
www.OncotypeDX.com, www.mybreastcancertreatment.org and
www.myprostatecancertreatment.org.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the attributes and focus of the company's product pipeline; the
applicability of clinical study results to actual outcomes; the ability of any
potential tests the company may develop to optimize cancer treatment and the
potential economic benefits associated with the company's tests; the ability
of the company to develop additional tests in the future; the size of markets
and demand for the company's tests; and the company's ability to commercialize
new tests and expand into new markets domestically and internationally.
Forward-looking statements are subject to risks and uncertainties that could
cause actual results to differ materially, and reported results should not be
considered as an indication of future performance. These risks and
uncertainties include, but are not limited to: the risks and uncertainties
associated with the regulation of the company's tests; the results of clinical
studies; the applicability of clinical study results to actual outcomes; our
ability to develop and commercialize new tests; the risk that the company may
not obtain or maintain sufficient levels of reimbursement, domestically or
abroad, for its existing tests and any future tests it may develop; the risks
of competition; unanticipated costs or delays in research and development
efforts and our ability to obtain capital when needed and the other risks set
forth in the company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's Quarterly Report on Form 10-Q
for the period ended September 30, 2013. These forward-looking statements
speak only as of the date hereof. Genomic Health disclaims any obligation to
update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective
owners.

SOURCE Genomic Health, Inc.

Website: http://www.genomichealth.com
Contact: Investors: Dean Schorno, Genomic Health, 650-569-2281,
investors@genomichealth.com or Media: Emily Faucette, Genomic Health,
650-569-2824, media@genomichealth.com
 
Press spacebar to pause and continue. Press esc to stop.